Category from the VIM tool | Phase 1 | Phase 3 |
---|---|---|
112 patients | 16 patients | |
Management—investigations, e.g. fields test | 88% (99) | 100% (16) |
Self-management—importance of taking eyedrops | 83% (93) | 100% (16) |
Management—regular monitoring | 63% (70) | 81% (13) |
Management—appointment issues | 63% (70) | 94% (15) |
Treatment—options for eyedrops | 60% (67) | 100% (16) |
Risk—family | 55% (62) | 100% (16) |
Diagnosis | 54% (60) | 100% (16) |
Treatment—side effects | 43% (48) | 100% (16) |
Prognosis—loss of sight | 24% (27) | 100% (16) |
Driving | 16% (18) | 94% (15) |
Support—help with eyedrops | 13% (15) | 100% (16) |
Prognosis—symptomless | 11% (12) | 100% (16) |
Prognosis—sight can’t be recovered | 10% (11) | 100% (16) |
Support—support groups | 10% (11) | 94% (15) |
Prognosis—when treated most don’t go blind | 3% (3) | 100% (16) |
Registration of loss of sight | 2% (2) | 6% (1) |